1182 related articles for article (PubMed ID: 17059876)
1. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
[TBL] [Abstract][Full Text] [Related]
2. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
3. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002).
Biedenbach DJ; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):59-69. PubMed ID: 15380279
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents.
Fedler KA; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):427-36. PubMed ID: 16938419
[TBL] [Abstract][Full Text] [Related]
5. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
6. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
8. Molecular epidemiology of selected multidrug-resistant bacteria: a global report from the SENTRY Antimicrobial Surveillance Program.
Deshpande LM; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2004 Aug; 49(4):231-6. PubMed ID: 15313526
[TBL] [Abstract][Full Text] [Related]
9. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
Bertrand X; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
[TBL] [Abstract][Full Text] [Related]
11. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns.
Sader HS; Jones RN; Silva JB;
Diagn Microbiol Infect Dis; 2002 Nov; 44(3):281-8. PubMed ID: 12493176
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003).
Streit JM; Jones RN; Toleman MA; Stratchounski LS; Fritsche TR
Int J Antimicrob Agents; 2006 May; 27(5):367-75. PubMed ID: 16647842
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centres.
Sader HS; Farrell DJ; Jones RN
Int J Antimicrob Agents; 2010 Jul; 36(1):28-32. PubMed ID: 20444576
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
Biedenbach DJ; Toleman M; Walsh TR; Jones RN
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
[TBL] [Abstract][Full Text] [Related]
17. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN
Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
19. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
